Pharma BD Deal Intelligence
Gilead Sciences Inc. / CV Therapeutics Inc.
2009 · Acquisition/Merger · $1.4B · Complete
Announcement Sentiment
63
Positive
Outcome Score
62
Largely worked — most objectives met.
Gilead acquired CV Therapeutics for $1.4B for Ranexa and Lexiscan.
Did it work? Outcome assessment
Gilead / CV Therapeutics: Partially Achieved (Score: 64/100)
Strategic verdict
Partially Achieved
Assessment window: 15yr post-close.
Key facts
- Announced Mar 12, 2009
- Closed Apr 17, 2009
- Deal value $1.4B
- Deal type Acquisition/Merger
- Therapeutic area Cardiovascular
- Key assets Ranexa
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals